Literature DB >> 8567676

Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1.

D K Bhattacharyya1, M Lecomte, C J Rieke, M Garavito, W L Smith.   

Abstract

Examination of the crystal structure of the ovine prostaglandin endoperoxide synthase-1 (PGHS-1)/S- flurbiprofen complex (Picot, D., Loll, P.J., and Garavito, R.M. (1994) Nature 367, 243-2491) suggests (a) that the carboxyl group of arachidonic acid interacts with the arginino group of Arg120; (b) that Arg120 forms an important salt bridge with Glu524; and (c) that Tyr355, which is in close proximity to Arg120, could determine the stereochemical specificity of PGHS-1 toward 2-phenylpropionic acid inhibitors. To test these concepts, we used site-directed mutagenesis to prepare ovine PGHS-1 mutants having modifications of Arg120 (R120K, R120Q, R120E), Glu524 (E524D, E524Q, E524K), and Tyr355 (Y355F) and examined the properties of the mutant enzymes expressed in COS-1 cells. All of the mutants retained at least part of their cyclooxygenase and peroxidase activities except the R120E mutant, which had no detectable activity. The Km values of the R120K and R120Q mutants with arachidonic acid were 87 and 3300 microM, respectively, versus 4 microM for native PGHS-1. The R120Q mutant failed to undergo suicide inactivation during catalysis or time-dependent inhibition by flurbiprofen. These results are consistent with Arg120 binding the carboxylate group of arachidonate and suggest that interaction of the carboxylate group of substrates and inhibitors with Arg120 is necessary for suicide inactivation and time-dependent inhibition, respectively. The Km values for the E524D, E524Q, and E524K mutants were not significantly different from values obtained for the native PGHS-1, suggesting that this residue is not importantly involved in catalysis or substrate binding. The effect of modifications of Arg120 and Tyr355 on the stereospecificity of inhibitor binding was determined. Ratios of IC50 values for cyclooxygenase inhibition by D- and L-ibuprofen, a competitive cyclooxygenase inhibitor, were 32, 67, and 7.1 for native PGHS-1, R120Q PGHS-1, and Y355F PGHS-1, respectively. The decreased stereochemical specificity observed with the Y355F PGHS-1 mutant suggests that Tyr355 is a determinant of the stereospecificity of PGHS-1 toward inhibitors of the 2-phenylpropionic acid class.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8567676     DOI: 10.1074/jbc.271.4.2179

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).

Authors:  R García-Nieto; C Pérez; F Gago
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

2.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

Authors:  M C Walker; R G Kurumbail; J R Kiefer; K T Moreland; C M Koboldt; P C Isakson; K Seibert; J K Gierse
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

3.  Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Authors:  Md Jashim Uddin; Brenda C Crews; Anna L Blobaum; Philip J Kingsley; D Lee Gorden; J Oliver McIntyre; Lynn M Matrisian; Kotha Subbaramaiah; Andrew J Dannenberg; David W Piston; Lawrence J Marnett
Journal:  Cancer Res       Date:  2010-05-01       Impact factor: 12.701

4.  Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.

Authors:  A S Kalgutkar; B C Crews; S W Rowlinson; A B Marnett; K R Kozak; R P Remmel; L J Marnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 5.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

6.  An Activity-Based Sensing Approach for the Detection of Cyclooxygenase-2 in Live Cells.

Authors:  Anuj K Yadav; Christopher J Reinhardt; Andres S Arango; Hannah C Huff; Liang Dong; Michael G Malkowski; Aditi Das; Emad Tajkhorshid; Jefferson Chan
Journal:  Angew Chem Int Ed Engl       Date:  2020-02-06       Impact factor: 15.336

Review 7.  Interactions of fatty acids, nonsteroidal anti-inflammatory drugs, and coxibs with the catalytic and allosteric subunits of cyclooxygenases-1 and -2.

Authors:  William L Smith; Michael G Malkowski
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

8.  Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases.

Authors:  Qing Jiang; Xinmin Yin; Markus A Lill; Matthew L Danielson; Helene Freiser; Jianjie Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-11       Impact factor: 11.205

9.  Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit.

Authors:  Liang Dong; Chong Yuan; Benjamin J Orlando; Michael G Malkowski; William L Smith
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

10.  Modulation of glutamate and glycine transporters by niflumic, flufenamic and mefenamic acids.

Authors:  Suzanne Habjan; Robert J Vandenberg
Journal:  Neurochem Res       Date:  2009-05-15       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.